Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Clinical Study of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defect
Details : ZKY001 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Corneal Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2025
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZKY001 Eye Drops Safety and Efficacy In Neurotrophic Keratitis
Details : ZKY001 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Corneal Epithelial Defect.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 13, 2025
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
Details : Brimonidine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Presbyopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2025
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine A is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinastine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epinastine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2024
Lead Product(s) : Epinastine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects in a Phase â…¡ Clinical Trial
Details : ZKY001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Epithelial Defect.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 19, 2024
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Atropine sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Details : Atropine sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myopia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ZKY001 Eye Drops
Details : ZKY001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Epithelial Defect.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : ZKY001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable